MCID: PNC041
MIFTS: 67

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 37 12 14 69
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 46 C9120
UMLS 69 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to adenocarcinoma and adenosquamous pancreas carcinoma, and has symptoms including pruritus, icterus and abdominal pain. An important gene associated with Pancreatic Ductal Adenocarcinoma is KRAS (KRAS Proto-Oncogene, GTPase), and among its related pathways/superpathways are ERK Signaling and PAK Pathway. The drugs Gemcitabine and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, pancreas and lymph node, and related phenotypes are Decreased viability and Decreased viability

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 182)
# Related Disease Score Top Affiliating Genes
1 adenocarcinoma 31.1 AKT1 CDH1 CDKN2A CTNNB1 EGFR HRAS
2 adenosquamous pancreas carcinoma 30.5 HRAS KRAS SMAD4
3 cholangiocarcinoma 30.3 CDH1 KRAS MUC1 MUC4 SMAD4
4 bile duct carcinoma 30.2 CDH1 MUC1 MUC4 TP53
5 adenosquamous carcinoma 30.2 EGFR KRAS MUC1 MUC4 TP53
6 gastric adenocarcinoma 30.0 CDH1 CTNNB1 HRAS MUC4 SMAD4
7 breast cancer 28.6 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
8 pancreatic cancer 28.6 AKT1 AREG CDH1 CDKN2A CTNNB1 EGFR
9 gastric cancer 28.5 AKT1 AREG CDH1 CDKN2A CTNNB1 EGFR
10 pancreas adenocarcinoma 26.5 AKT1 AREG CDH1 CDKN2A CTNNB1 EGFR
11 pancreatitis 11.3
12 mutyh-associated polyposis 10.6 KRAS SMAD4 TP53
13 pulmonary blastoma 10.6 EGFR KRAS TP53
14 brain ependymoma 10.6 EGFR TP53
15 ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3 10.6 CTNNB1 KRAS TP53
16 squamous cell carcinoma of the larynx 10.6 CDKN2A EGFR TP53
17 brain stem astrocytic neoplasm 10.6 CDKN2A TP53
18 esophageal basaloid squamous cell carcinoma 10.6 CTNNB1 EGFR TP53
19 oropharynx cancer 10.6 CDKN2A EGFR TP53
20 acinar cell carcinoma 10.6 CTNNB1 SMAD4 TP53
21 basaloid squamous cell carcinoma 10.6 CDKN2A EGFR TP53
22 gastric adenosquamous carcinoma 10.6 CDKN2A EGFR PROM1
23 adult hepatocellular carcinoma 10.5 CTNNB1 TP53
24 barrett's adenocarcinoma 10.5 CDKN2A KRAS TP53
25 vulva cancer 10.5 CDKN2A EGFR TP53
26 anal squamous cell carcinoma 10.5 AKT1 CDKN2A TP53
27 breast metaplastic carcinoma 10.5 CDH1 EGFR TP53
28 malignant peritoneal mesothelioma 10.5 CDKN2A EGFR MUC1
29 sigmoid neoplasm 10.5 HRAS KRAS
30 paronychia 10.5 EGFR HRAS KRAS
31 pseudomyxoma peritonei 10.5 KRAS MUC1 TP53
32 lung adenoid cystic carcinoma 10.5 EGFR HRAS KRAS
33 grade iii astrocytoma 10.5 CDKN2A EGFR TP53
34 infratentorial cancer 10.5 CTNNB1 PROM1 TP53
35 ovary adenocarcinoma 10.5 HRAS KRAS TP53
36 mixed cell type cancer 10.5 HRAS KRAS TP53
37 acneiform dermatitis 10.5 EGFR HRAS KRAS
38 spitz nevus 10.5 CDKN2A HRAS TP53
39 lobular neoplasia 10.5 CDH1 CTNNB1 MUC1
40 pleural cancer 10.5 AKT1 CDKN2A MSLN
41 peritoneal mesothelioma 10.5 CDKN2A EGFR MUC1
42 epstein-barr virus-associated gastric carcinoma 10.5 CDH1 CDKN2A CTNNB1
43 cholangiolocellular carcinoma 10.5 CDKN2A MUC1 PROM1
44 peutz-jeghers syndrome 10.5 CTNNB1 SMAD4 TP53
45 cervical adenocarcinoma 10.5 CDKN2A EGFR TP53
46 liver angiosarcoma 10.5 HRAS KRAS TP53
47 adenosquamous cell lung carcinoma 10.5 EGFR HRAS KRAS
48 pre-malignant neoplasm 10.5 CDH1 CDKN2A EGFR TP53
49 meningeal melanomatosis 10.5 CDKN2A HRAS TP53
50 in situ carcinoma 10.5 CDH1 CDKN2A EGFR TP53

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


pruritus, icterus, abdominal pain

GenomeRNAi Phenotypes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

25
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 9.88 EGFR HRAS KRAS MUC1
2 Decreased viability GR00106-A-0 9.88 KRAS
3 Decreased viability GR00221-A-1 9.88 EGFR HRAS KRAS AKT1 CDH1 CDKN2A
4 Decreased viability GR00221-A-2 9.88 HRAS KRAS AKT1
5 Decreased viability GR00221-A-3 9.88 HRAS AKT1 CDKN2A
6 Decreased viability GR00221-A-4 9.88 EGFR AKT1 CDKN2A
7 Decreased viability GR00301-A 9.88 KRAS CDH1
8 Decreased viability GR00381-A-1 9.88 KRAS
9 Decreased cell migration GR00055-A-1 9.43 HRAS KRAS AKT1 CTNNB1 EGFR MUC1

MGI Mouse Phenotypes related to Pancreatic Ductal Adenocarcinoma:

43 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.37 EGFR CTNNB1 HRAS PROM1 CDH1 KRAS
2 homeostasis/metabolism MP:0005376 10.37 EGFR CTNNB1 HRAS CDH1 KRAS AKT1
3 growth/size/body region MP:0005378 10.35 EGFR CTNNB1 HRAS SLC29A1 PROM1 CDH1
4 behavior/neurological MP:0005386 10.34 CTNNB1 HRAS SLC29A1 PROM1 KRAS AKT1
5 endocrine/exocrine gland MP:0005379 10.33 KRAS HRAS EGFR CDH1 CTNNB1 AKT1
6 cellular MP:0005384 10.32 EGFR CTNNB1 CDKN2A PROM1 CDH1 AKT1
7 digestive/alimentary MP:0005381 10.27 KRAS CTNNB1 HRAS EGFR CDH1 PTF1A
8 embryo MP:0005380 10.21 EGFR CTNNB1 CDH1 KRAS AKT1 PTF1A
9 integument MP:0010771 10.21 EGFR CTNNB1 HRAS CDH1 KRAS AKT1
10 neoplasm MP:0002006 10.2 KRAS HRAS EGFR CDH1 CTNNB1 AKT1
11 nervous system MP:0003631 10.17 EGFR CTNNB1 HRAS PROM1 KRAS AKT1
12 craniofacial MP:0005382 10.12 HRAS EGFR CTNNB1 KRAS PTF1A TP53
13 normal MP:0002873 10.11 CTNNB1 HRAS EGFR PROM1 CDH1 KRAS
14 no phenotypic analysis MP:0003012 10.1 KRAS HRAS EGFR CDH1 CTNNB1 PTF1A
15 liver/biliary system MP:0005370 10.08 EGFR CTNNB1 KRAS AKT1 PTF1A CDKN2A
16 limbs/digits/tail MP:0005371 10.04 EGFR CTNNB1 SLC29A1 KRAS PTF1A TP53
17 reproductive system MP:0005389 9.96 EGFR CTNNB1 CDH1 KRAS AKT1 CDKN2A
18 pigmentation MP:0001186 9.8 EGFR CTNNB1 PROM1 KRAS CDKN2A TP53
19 respiratory system MP:0005388 9.76 EGFR CTNNB1 HRAS KRAS AKT1 PTF1A
20 skeleton MP:0005390 9.65 EGFR CTNNB1 HRAS SLC29A1 KRAS AKT1
21 vision/eye MP:0005391 9.23 EGFR CTNNB1 PROM1 KRAS PTF1A AREG

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 139)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Gemcitabine Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 95058-81-4 60750
2
Paclitaxel Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 33069-62-4 36314
3 Albumin-Bound Paclitaxel Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
4 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
5 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
6 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
7 Antimitotic Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
8 Antineoplastic Agents, Phytogenic Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
9 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
10 Immunosuppressive Agents Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1
11
Fluorouracil Approved Phase 3,Phase 2,Phase 1 51-21-8 3385
12
Pancrelipase Approved, Investigational Phase 3,Phase 1,Phase 2,Early Phase 1 53608-75-6
13
Capecitabine Approved, Investigational Phase 3,Phase 2,Phase 1 154361-50-9 60953
14
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741 24759
15 acivicin Phase 3,Phase 2
16 Protective Agents Phase 3,Phase 2,Phase 1
17 pancreatin Phase 3,Phase 1,Phase 2,Early Phase 1
18 Adjuvants, Immunologic Phase 3
19 Viscosupplements Phase 3
20
Erlotinib Hydrochloride Phase 3,Phase 1,Phase 2 183319-69-9 176871
21 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
22
Cisplatin Approved Phase 1, Phase 2 15663-27-1 2767 441203 84093
23
Irinotecan Approved, Investigational Phase 2,Phase 1 97682-44-5, 100286-90-6 60838
24
Oxaliplatin Approved, Investigational Phase 2,Phase 1 61825-94-3 43805 6857599 5310940 9887054
25
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
26
Rucaparib Approved, Investigational Phase 2 283173-50-2 9931954
27
Carboplatin Approved Phase 2,Phase 1 41575-94-4 10339178 38904 498142
28
Propofol Approved, Investigational, Vet_approved Phase 2,Phase 1 2078-54-8 4943
29
nivolumab Approved Phase 2,Phase 1 946414-94-4
30
Coal tar Approved Phase 1, Phase 2 8007-45-2
31
Levoleucovorin Approved, Investigational Phase 2,Phase 1 68538-85-2
32
Olaparib Approved Phase 2 763113-22-0 23725625
33
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
34
Cyclophosphamide Approved, Investigational Phase 1, Phase 2 50-18-0, 6055-19-2 2907
35
Pembrolizumab Approved Phase 1, Phase 2 1374853-91-4
36
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 60843 446556
37
Niraparib Approved, Investigational Phase 1, Phase 2 1038915-60-4 24958200
38
Metformin Approved Phase 2 657-24-9 4091 14219
39
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
40
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2,Phase 1 59-30-3 6037
41
leucovorin Approved, Nutraceutical Phase 2,Phase 1 58-05-9 143 6006
42
Ergocalciferol Approved, Nutraceutical Phase 2 50-14-6 5280793
43
Vitamin C Approved, Nutraceutical Phase 1, Phase 2 50-81-7 54670067 5785
44
Camptothecin Experimental Phase 2,Phase 1 7689-03-4
45
Tremelimumab Investigational Phase 2,Phase 1 745013-59-6
46
Doxil Approved June 1999 Phase 2 31703
47
Cediranib Investigational Phase 2 288383-20-0 9933475
48
Maleic acid Experimental Phase 2 110-16-7 444266
49 Misonidazole Investigational Phase 2 13551-87-6
50 Antidotes Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 137)

# Name Status NCT ID Phase Drugs
1 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Unknown status NCT02570529 Phase 4 Albis®;Placebo
2 The Effect of Gemcitabine Plus Nab-paclitaxel as Secondary Chemotherapy in Advanced Pancreatic Cancer Recruiting NCT03401827 Phase 4 Chemotherapy (Gemcitabine + nab-paclitaxel)
3 A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenoca Recruiting NCT02715804 Phase 3 Placebo;Nab-paclitaxel;Gemcitabine
4 A Study of Napabucasin Plus Nab-Paclitaxel With Gemcitabine in Adult Patients With Metastatic Pancreatic Adenocarcinoma Recruiting NCT02993731 Phase 3 Napabucasin;Nab-paclitaxel;Gemcitabine
5 Gemcitabine Hydrochloride With or Without Erlotinib Hydrochloride Followed By the Same Chemotherapy Regimen With or Without Radiation Therapy and Capecitabine or Fluorouracil in Treating Patients With Pancreatic Cancer That Has Been Removed By Surgery Recruiting NCT01013649 Phase 3 Capecitabine;Chemotherapy;Erlotinib Hydrochloride;Fluorouracil;Gemcitabine Hydrochloride
6 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer Not yet recruiting NCT03317886 Phase 3
7 Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Participants With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
8 Nab-Paclitaxel+Cisplatin+Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Unknown status NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
9 Modulation of the Immune Response in Patients With Pancreatic Tubular Adenocarcinoma Unknown status NCT01021800 Phase 2
10 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Unknown status NCT02440958 Phase 2 modified FOLFIRINOX regimen
11 Nab-paclitaxel Plus Gemcitabine in Chinese Patients With Advanced Pancreatic Cancer Unknown status NCT02135822 Phase 2 nanoparticle albumin-bound paclitaxel;gemcitabine
12 Phase II Study of MEDI4736 Monotherapy or in Combinations With Tremelimumab in Metastatic Pancreatic Ductal Carcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
13 Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
14 Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Completed NCT01580397 Phase 2 INNO-206
15 A Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation Completed NCT02042378 Phase 2 Rucaparib
16 Capecitabine and Oxaliplatin in Patients With Advanced or Metastatic Pancreatic Adenocarcinoma Completed NCT00585078 Phase 2 Capecitabine;Oxaliplatin
17 Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy Completed NCT01658943 Phase 2 Akt Inhibitor MK2206;Fluorouracil;Oxaliplatin;Selumetinib
18 Carboplatin and Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Metastatic Pancreatic Cancer Completed NCT01280058 Phase 2 Carboplatin;Paclitaxel
19 Phase Ib/II Study of MEDI4736 Evaluated in Different Combinations in Metastatic Pancreatic Ductal Carcinoma Recruiting NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
20 Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
21 Combination Therapy for Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
22 A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040
23 PEGPH20, Gemicitabine and Nab-Paclitaxel for Pancreatic Ductal Adenocarcinoma Recruiting NCT02487277 Phase 2 PEGPH20;Gemcitabine;Nab-paclitaxel
24 A Phase II Study of Neoadjuvant FOLFIRINOX Recruiting NCT02178709 Phase 2 FOLFIRINOX
25 Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors Recruiting NCT02810418 Phase 1, Phase 2 LMB-100;Nab-Paclitaxel
26 A Study of Durvalumab in Patients With BR PDA Following Neoadjuvant Therapy and Successful Surgical Resection Recruiting NCT03038477 Phase 2 Durvalumab
27 Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) Recruiting NCT03415854 Phase 2 Paricalcitol (Zemplar)
28 Study of NAC of GA Therapy for Patients With BRPC Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
29 Perioperative Therapy for Resectable and Borderline-Resectable Pancreatic Adenocarcinoma With Molecular Correlates Recruiting NCT02723331 Phase 2 Nab-paclitaxel and gemcitabine for R-PDAC Patients;Nab-paclitaxel and gemcitabine for BR-PDAC Patients
30 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol
31 A Phase 2 Study of siG12D LODER in Combination With Chemotherapy in Patients With Locally Advanced Pancreatic Cancer Recruiting NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
32 Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Recruiting NCT02125136 Phase 2 Gem/nab-Pac;FOLFIFINOX
33 Neoadjuvant Plus Adjuvant or Only Adjuvant Nab- Paclitaxel Plus Gemcitabine for Resectable Pancreatic Cancer Recruiting NCT02047513 Phase 2 perioperative nab-paclitaxel/gemcitabine;adjuvant nab-paclitaxel/gemcitabine
34 Ibrutinib Combined With Gemcitabine and Nab-Paclitaxel in Patients With Metastatic Pancreatic Cancer Recruiting NCT02562898 Phase 1, Phase 2 Ibrutinib;Paclitaxel;Gemcitabine
35 Effect of Intratumoral Injection of Gene Therapy for Locally Advanced Pancreatic Cancer Recruiting NCT02806687 Phase 2 Gene Therapy product CYL-02;Gemcitabine
36 Efficacy and Safety of PARPi to Treat Pancreatic Cancer Recruiting NCT02511223 Phase 2 OLAPARIB
37 Near-infrared Image Guided Surgery in Pancreatic Adenocarcinoma Recruiting NCT02743975 Phase 1, Phase 2 Bevacizumab-800CW
38 A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Recruiting NCT03267316 Phase 1, Phase 2
39 A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Recruiting NCT03085914 Phase 1, Phase 2 Epacadostat;Pembrolizumab;Oxaliplatin;Leucovorin;5-Fluorouracil;Gemcitabine;nab-Paclitaxel;Carboplatin;Paclitaxel;Pemetrexed;Cyclophosphamide;Carboplatin;Cisplatin
40 Trial of Ascorbic Acid (AA) + Nanoparticle Paclitaxel Protein Bound + Cisplatin + Gemcitabine (AA NABPLAGEM) Recruiting NCT03410030 Phase 1, Phase 2 Ascorbic Acid;Paclitaxel protein-bound;Cisplatin;Gemcitabine
41 Phase I/II Study of IMMU-132 in Patients With Epithelial Cancers Recruiting NCT01631552 Phase 1, Phase 2 IMMU-132
42 A Phase 2 Study of Cediranib in Combination With Olaparib in Advanced Solid Tumors Recruiting NCT02498613 Phase 2 Cediranib Maleate;Olaparib
43 Niraparib + Ipilimumab or Nivolumab in Progression Free Pancreatic Adenocarcinoma After Platinum-Based Chemotherapy Recruiting NCT03404960 Phase 1, Phase 2 Niraparib + Nivolumab;Niraparib + Ipilimumab
44 Olaparib for BRCAness Phenotype in Pancreatic Cancer Recruiting NCT02677038 Phase 2 Olaparib
45 A Study of Abemaciclib (LY2835219) Alone or in Combination With Other Agents in Participants With Previously Treated Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
46 Study of Tremelimumab in Patients With Advanced Solid Tumors Active, not recruiting NCT02527434 Phase 2
47 Nab-paclitaxel Plus S-1 in Patients With Advanced Pancreatic Cancer Active, not recruiting NCT02124317 Phase 2 nanoparticle albumin-bound paclitaxel;S-1
48 Phase 2 Evaluation of Multi-modality Algorithm for Non-metastatic Adenocarcinoma of Pancreas or Ampulla Active, not recruiting NCT02626520 Phase 2 Gemcitabine and nanoparticle albumin bound paclitaxel;5-fluorouracil and irinotecan
49 Gemcitabine + Nab-paclitaxel With LDE-225 (Hedgehog Inhibitor) as Neoadjuvant Therapy for Pancreatic Adenocarcinoma Active, not recruiting NCT01431794 Phase 1, Phase 2 LDE-225;Gemcitabine;nab-paclitaxel
50 The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Not yet recruiting NCT02978547 Phase 2 Metformin Hydrochloride 500Mg Tablet

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

38
Pancreas, Lymph Node, T Cells, Breast, Liver, Neutrophil, Testes
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 971)
# Title Authors Year
1
MiR-7-5p functions as a tumor suppressor by targeting SOX18 in pancreatic ductal adenocarcinoma. ( 29408481 )
2018
2
Fibrosis-related miRNAs as serum biomarkers for pancreatic ductal adenocarcinoma. ( 29435115 )
2018
3
Pyruvate kinase type M2 contributes to the development of pancreatic ductal adenocarcinoma by regulating the production of metabolites and reactive oxygen species. ( 29393401 )
2018
4
A phase I trial of the I^-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. ( 29438372 )
2018
5
High expression of microRNA-4295 contributes to cell proliferation and invasion of pancreatic ductal adenocarcinoma by the down-regulation of Glypican-5. ( 29407175 )
2018
6
High expression of RACK1 is associated with poor prognosis in patients with pancreatic ductal adenocarcinoma. ( 29434907 )
2018
7
The role of miRNAs in the diagnosis, chemoresistance, and prognosis of pancreatic ductal adenocarcinoma. ( 29416345 )
2018
8
Decreased Skeletal Muscle Volume Is a Predictive Factor for Poorer Survival in Patients Undergoing Surgical Resection for Pancreatic Ductal Adenocarcinoma. ( 29392613 )
2018
9
Imaging features of pancreatic metastases: A comparison with pancreatic ductal adenocarcinoma. ( 29448123 )
2018
10
Significance of Glucose Transporter Type 1 (GLUT-1) Expression in the Therapeutic Strategy for Pancreatic Ductal Adenocarcinoma. ( 29404819 )
2018
11
"International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017": Will this pull us up out of the quagmire of confusing definitions and criteria? ( 29389525 )
2018
12
Intravoxel incoherent motion magnetic resonance imaging for differentiating metastatic and non-metastatic lymph nodes in pancreatic ductal adenocarcinoma. ( 29404768 )
2018
13
Determinants and prognostic value of quality of life in patients with pancreatic ductal adenocarcinoma. ( 29413686 )
2018
14
Incremental Role of Pancreatic Magnetic Resonance Imaging after Staging Computed Tomography to Evaluate Patients with Pancreatic Ductal Adenocarcinoma. ( 29397657 )
2018
15
Comprehensive characterisation of compartment-specific long non-coding RNAs associated with pancreatic ductal adenocarcinoma. ( 29440233 )
2018
16
Silver nanoparticles of different sizes induce a mixed type of programmed cell death in human pancreatic ductal adenocarcinoma. ( 29435134 )
2018
17
Overexpression of FZD1 and CAIX are Associated with Invasion, Metastasis, and Poor-Prognosis of the Pancreatic Ductal Adenocarcinoma. ( 28921449 )
2017
18
The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice? ( 29387699 )
2017
19
Selection of optimal molecular targets for tumor-specific imaging in pancreatic ductal adenocarcinoma. ( 28915633 )
2017
20
APE1/Ref-1 knockdown in pancreatic ductal adenocarcinoma: Characterizing gene expression changes and identifying novel pathways using single-cell RNA sequencing. ( 28922540 )
2017
21
A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. ( 28350132 )
2017
22
Lipocalin-2 Promotes Pancreatic Ductal Adenocarcinoma by Regulating Inflammation in the Tumor Microenvironment. ( 28249896 )
2017
23
Increased expression of calponin 2 is a positive prognostic factor in pancreatic ductal adenocarcinoma. ( 28915602 )
2017
24
The prognostic significance of cancer-associated fibroblasts in pancreatic ductal adenocarcinoma. ( 29025374 )
2017
25
COMMD7 functions as molecular target in pancreatic ductal adenocarcinoma. ( 27350032 )
2017
26
Corrigendum to "Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis". ( 28912624 )
2017
27
KRAS Mutations With No GNAS Mutations in an Intraductal Papillary Mucinous Neoplasm: Are There Common Pathways With Pancreatic Ductal Adenocarcinoma? Lessons From an Extended IPMN, Covering the Entire Pancreas. ( 27977634 )
2017
28
MUC13 interaction with receptor tyrosine kinase HER2 drives pancreatic ductal adenocarcinoma progression. ( 27321183 )
2017
29
The prognostic relevance of primary tumor location in patients undergoing resection for pancreatic ductal adenocarcinoma. ( 28122349 )
2017
30
Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma. ( 27546622 )
2017
31
The FOXO3/PGC-1I^ signaling axis is essential for cancer stem cell properties of pancreatic ductal adenocarcinoma. ( 28507102 )
2017
32
DEK protein overexpression predicts poor prognosis in pancreatic ductal adenocarcinoma. ( 27959420 )
2017
33
The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: EUS oriented. ( 29387698 )
2017
34
The extracellular matrix and focal adhesion kinase signaling regulate cancer stem cell function in pancreatic ductal adenocarcinoma. ( 28692661 )
2017
35
Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma. ( 28060763 )
2017
36
Co-targeting of EGF receptor and neuropilin-1 overcomes cetuximab resistance in pancreatic ductal adenocarcinoma with integrin I^1-driven Src-Akt bypass signaling. ( 27797376 )
2017
37
Refining the American Joint Committee on Cancer Staging Scheme For Resectable Pancreatic Ductal Adenocarcinoma Using Recursive Partitioning Analysis. ( 28928865 )
2017
38
Lin28B facilitates the progression and metastasis of pancreatic ductal adenocarcinoma. ( 28947981 )
2017
39
The DPC4/SMAD4 genetic status determines recurrence patterns and treatment outcomes in resected pancreatic ductal adenocarcinoma: A prospective cohort study. ( 28160547 )
2017
40
UNR/CDSE1 expression as prognosis biomarker in resectable pancreatic ductal adenocarcinoma patients: A proof-of-concept. ( 28763470 )
2017
41
Prognostic value of postdiagnostic inflammation-based scores in short-term overall survival of advanced pancreatic ductal adenocarcinoma patients. ( 29390358 )
2017
42
Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma. ( 28220683 )
2017
43
Integrated Genomic Characterization of Pancreatic Ductal Adenocarcinoma. ( 28810144 )
2017
44
Tissue-Resident Macrophages in Pancreatic Ductal Adenocarcinoma Originate from Embryonic Hematopoiesis and Promote Tumor Progression. ( 28930665 )
2017
45
Novel p21-Activated Kinase 4 (PAK4) Allosteric Modulators Overcome Drug Resistance and Stemness in Pancreatic Ductal Adenocarcinoma. ( 28062705 )
2017
46
NEMO peptide inhibits the growth of pancreatic ductal adenocarcinoma by blocking NF-I_B activation. ( 28951128 )
2017
47
Simvastatin attenuates macrophage-mediated gemcitabine resistance of pancreatic ductal adenocarcinoma by regulating the TGF-I^1/Gfi-1 axis. ( 27840243 )
2017
48
Immunotherapy in Pancreatic Ductal Adenocarcinoma: An Emerging Entity? ( 28945842 )
2017
49
Connexin-43 channels are a pathway for discharging lactate from glycolytic pancreatic ductal adenocarcinoma cells. ( 28368405 )
2017
50
DPC4 gene expression in primary pancreatic ductal adenocarcinoma: relationship with CT characteristics. ( 28339284 )
2017

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 (zymogen granule membrane) Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin peptidase inhibitor, clade I (pancpin), member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin-like elastase family, member 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase-related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A, member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin-like Pancreas - 7.52 0.000
10 COL10A1 collagen, type X, alpha 1 Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen, type V, alpha 1 Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida-like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin, osteoblast specific factor Pancreas + 7.24 0.000
16 COL1A1 collagen, type I, alpha 1 Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 carcinoembryonic antigen-related cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen, type XI, alpha 1 Pancreas + 7.00 0.000
20 CLPS colipase, pancreatic Pancreas - 6.99 0.000
21 INHBA inhibin, beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 (pancreatic) Pancreas - 6.88 0.000
23 CTRC chymotrypsin C (caldecrin) Pancreas - 6.87 0.000
24 CEACAM6 carcinoembryonic antigen-related cell adhesion molecule 6 (non-specific cross reacting antigen) Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2, group IB (pancreas) Pancreas - 6.79 0.001
26 COL3A1 collagen, type III, alpha 1 Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled-related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin-like elastase family, member 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen, type I, alpha 2 Pancreas + 6.72 0.000
31 REG1P regenerating islet-derived 1 pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin-like elastase family, member 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 (pancreatic) Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating islet-derived 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 (liver, mitochondrial) Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein, beta 2, 26kDa Pancreas + 6.24 0.000
44 REG3G regenerating islet-derived 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen, type V, alpha 2 Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 (zinc transporter), member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show top 50) (show all 94)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.87 AKT1 AREG CDH1 CDKN2A CTNNB1 EGFR
2
Show member pathways
13.35 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
3
Show member pathways
13.34 AKT1 AREG CDH1 CTNNB1 EGFR HRAS
4
Show member pathways
13.13 AKT1 AREG EGFR HRAS KRAS TP53
5
Show member pathways
13.1 AKT1 CDKN2A CTNNB1 EGFR HRAS KRAS
6
Show member pathways
13.06 AKT1 CDH1 CDKN2A CTNNB1 EGFR HRAS
7
Show member pathways
13.05 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
8
Show member pathways
13.04 AKT1 CTNNB1 EGFR HRAS KRAS TP53
9
Show member pathways
12.95 AKT1 CTNNB1 HRAS KRAS TP53
10
Show member pathways
12.87 AKT1 CDKN2A HRAS KRAS TP53
11 12.85 AKT1 CDH1 CDKN2A CTNNB1 EGFR HRAS
12 12.82 AKT1 EGFR HRAS KRAS TP53
13
Show member pathways
12.79 AKT1 EGFR HRAS KRAS TP53
14
Show member pathways
12.79 AKT1 CDH1 CTNNB1 EGFR HRAS KRAS
15
Show member pathways
12.78 AKT1 CDH1 CTNNB1 HRAS KRAS TP53
16
Show member pathways
12.78 AKT1 CDH1 CDKN2A CTNNB1 EGFR HRAS
17
Show member pathways
12.73 AKT1 CTNNB1 EGFR HRAS KRAS
18
Show member pathways
12.73 AKT1 EGFR HRAS KRAS TP53
19
Show member pathways
12.65 AKT1 CTNNB1 EGFR HRAS KRAS TP53
20
Show member pathways
12.64 AKT1 CDKN2A EGFR HRAS KRAS TP53
21
Show member pathways
12.63 AKT1 CTNNB1 HRAS KRAS SMAD4 TP53
22 12.58 CDKN2A EGFR HRAS KRAS TP53
23
Show member pathways
12.56 AKT1 EGFR HRAS KRAS TP53
24
Show member pathways
12.53 AKT1 AREG EGFR HRAS KRAS TP53
25
Show member pathways
12.48 AKT1 CTNNB1 EGFR HRAS KRAS TP53
26
Show member pathways
12.46 AKT1 EGFR HRAS KRAS
27
Show member pathways
12.46 AKT1 CTNNB1 HRAS KRAS
28 12.45 AKT1 CDKN2A CTNNB1 HRAS KRAS SMAD4
29
Show member pathways
12.43 CTNNB1 HRAS KRAS TP53
30 12.43 CDH1 CDKN2A SMAD4 TP53
31
Show member pathways
12.42 AKT1 EGFR HRAS KRAS
32
Show member pathways
12.38 AKT1 EGFR HRAS KRAS
33 12.35 CDKN2A HRAS KRAS TP53
34
Show member pathways
12.32 AKT1 HRAS KRAS TP53
35 12.32 AKT1 CTNNB1 EGFR HRAS KRAS TP53
36
Show member pathways
12.29 AKT1 EGFR HRAS KRAS TP53
37
Show member pathways
12.29 AKT1 AREG EGFR HRAS KRAS
38 12.25 AKT1 EGFR HRAS KRAS
39
Show member pathways
12.24 AKT1 HRAS KRAS TP53
40 12.23 AKT1 CDKN2A HRAS KRAS TP53
41 12.22 AREG CDH1 CTNNB1 SMAD4
42
Show member pathways
12.21 AKT1 HRAS KRAS TP53
43
Show member pathways
12.2 AKT1 EGFR HRAS KRAS
44
Show member pathways
12.2 AKT1 HRAS KRAS TP53
45
Show member pathways
12.19 AKT1 CTNNB1 EGFR HRAS
46 12.19 AKT1 CDH1 CTNNB1 EGFR KRAS SMAD4
47 12.16 AKT1 CTNNB1 HRAS KRAS SMAD4
48
Show member pathways
12.15 AKT1 EGFR HRAS KRAS SMAD4
49 12.14 AKT1 CDH1 CTNNB1 EGFR KRAS SMAD4
50 12.13 AKT1 CDKN2A KRAS TP53

GO Terms for Pancreatic Ductal Adenocarcinoma

Cellular components related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 catenin complex GO:0016342 9.26 CDH1 CTNNB1
2 transcription factor complex GO:0005667 9.26 CTNNB1 PTF1A SMAD4 TP53
3 flotillin complex GO:0016600 9.16 CDH1 CTNNB1
4 vesicle GO:0031982 8.92 AKT1 MUC1 MUC4 PROM1

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

(show all 24)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.97 CDKN2A CTNNB1 HRAS KRAS TP53
2 positive regulation of apoptotic process GO:0043065 9.95 AKT1 CDKN2A CTNNB1 NUPR1 TP53
3 positive regulation of protein phosphorylation GO:0001934 9.86 AKT1 EGFR HRAS KRAS
4 stimulatory C-type lectin receptor signaling pathway GO:0002223 9.8 HRAS KRAS MUC1 MUC4
5 positive regulation of cell proliferation GO:0008284 9.8 AKT1 AREG CTNNB1 EGFR HRAS KRAS
6 positive regulation of MAP kinase activity GO:0043406 9.77 EGFR HRAS KRAS
7 positive regulation of transcription, DNA-templated GO:0045893 9.76 AKT1 CDH1 CDKN2A CTNNB1 EGFR PTF1A
8 cellular response to growth factor stimulus GO:0071363 9.74 AKT1 CTNNB1 EGFR
9 positive regulation of DNA replication GO:0045740 9.7 AREG EGFR HRAS
10 ERBB2 signaling pathway GO:0038128 9.69 EGFR HRAS KRAS
11 Ras protein signal transduction GO:0007265 9.67 CDKN2A HRAS KRAS TP53
12 cellular response to reactive oxygen species GO:0034614 9.65 AKT1 EGFR TP53
13 entry of bacterium into host cell GO:0035635 9.62 CDH1 CTNNB1
14 retina morphogenesis in camera-type eye GO:0060042 9.61 PROM1 PTF1A
15 response to isolation stress GO:0035900 9.61 HRAS KRAS
16 pancreas development GO:0031016 9.61 CTNNB1 MSLN PTF1A
17 positive regulation of cyclin-dependent protein serine/threonine kinase activity involved in G1/S transition of mitotic cell cycle GO:0031659 9.58 AKT1 EGFR
18 cellular response to indole-3-methanol GO:0071681 9.54 CDH1 CTNNB1
19 positive regulation of cellular senescence GO:2000774 9.5 CDKN2A KRAS MIR217
20 response to UV-A GO:0070141 9.46 AKT1 EGFR
21 epidermal growth factor receptor signaling pathway GO:0007173 9.35 AKT1 AREG EGFR HRAS KRAS
22 cell proliferation GO:0008283 9.23 AKT1 AREG CTNNB1 EGFR HRAS NUPR1
23 positive regulation of transcription by RNA polymerase II GO:0045944 10.01 AKT1 CDKN2A CTNNB1 EGFR HRAS PTF1A
24 negative regulation of cell proliferation GO:0008285 10 CDKN2A CTNNB1 HRAS SMAD4 TP53

Molecular functions related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein kinase binding GO:0019901 9.72 AKT1 CDKN2A CTNNB1 EGFR TP53
2 protein phosphatase binding GO:0019903 9.54 CTNNB1 EGFR TP53
3 I-SMAD binding GO:0070411 9.4 CTNNB1 SMAD4
4 RNA polymerase II transcription factor binding GO:0001085 9.33 CTNNB1 SMAD4 TP53
5 nitric-oxide synthase regulator activity GO:0030235 9.26 AKT1 EGFR
6 disordered domain specific binding GO:0097718 9.13 CDKN2A CTNNB1 TP53
7 chromatin binding GO:0003682 9.1 CTNNB1 EGFR NUPR1 PTF1A SMAD4 TP53

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....